Licain

Lidocaine, the active ingredient in Licain, is a local anesthetic presented as a sterile injectable solution for infiltration, intradermal, or intravenous use. It provides rapid, reversible loss of sensation in targeted tissues for minor surgical, dental, and diagnostic procedures. It is commonly used in outpatient settings and is recognized for its rapid onset and short duration of action.

GNH USA supplies Licain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable global distribution.

Licain (lidocaine) is employed to achieve local anesthesia in various minor procedures. - Minor surgical procedures: provides targeted numbness to facilitate pain‑free incision and manipulation. - Dental procedures: numbs oral tissues to allow painless extractions, restorations, and periodontal work. - Diagnostic endoscopic procedures: reduces discomfort during scope insertion and tissue sampling.

Lidocaine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Burning or stinging at the injection site - Tingling or mild numbness beyond the target area - Transient dizziness

Serious or Rare Side Effects: - Central nervous system toxicity such as seizures - Cardiac arrhythmias or hypotension - Allergic reactions including rash or anaphylaxis

When using Licain, several precautions should be observed to minimize risk. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: avoid or use with caution in patients with severe heart block or conduction abnormalities. - Maximum dose: do not exceed the recommended total dose for the specific route and patient weight. - Concomitant CNS depressants: monitor for additive central nervous system effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Lidocaine can interact with other medicines, influencing its plasma concentration or cardiac effects.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine levels and risk of toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic exposure.

Moderate Interactions (Monitor Closely): - Beta‑blockers or calcium‑channel blockers: may enhance lidocaine’s cardiac depressant effects. - Other local anesthetics: additive toxicity when combined. - Diuretics (e.g., furosemide): may alter plasma protein binding and increase free lidocaine.